MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 596752 | Name: Pegamotecan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Pegamotecan is a Topoisomerase-I inhibitor used as a treatment of Gastric and Gastroesophageal Junction Adenocarcinoma.

Chemical Structure

Pegamotecan
Pegamotecan
CAS#581079-18-7

Theoretical Analysis

MedKoo Cat#: 596752

Name: Pegamotecan

CAS#: 581079-18-7

Chemical Formula: C52H48N6O14

Exact Mass: 980.3229

Molecular Weight: 980.98

Elemental Analysis: C, 63.67; H, 4.93; N, 8.57; O, 22.83

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Pegamotecan; PEG-beta-CPT; PEG-camptothecin; Prothecan;
IUPAC/Chemical Name
(S)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl (2-(2-(2-(((S)-1-(((S)-4-ethyl-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl)oxy)-1-oxopropan-2-yl)amino)-2-oxoethoxy)ethoxy)acetyl)-L-alaninate
InChi Key
DZNNFZGDBUXWMV-ZUWDIFAMSA-N
InChi Code
InChI=1S/C52H48N6O14/c1-5-51(35-19-39-43-31(17-29-11-7-9-13-37(29)55-43)21-57(39)45(61)33(35)23-69-49(51)65)71-47(63)27(3)53-41(59)25-67-15-16-68-26-42(60)54-28(4)48(64)72-52(6-2)36-20-40-44-32(18-30-12-8-10-14-38(30)56-44)22-58(40)46(62)34(36)24-70-50(52)66/h7-14,17-20,27-28H,5-6,15-16,21-26H2,1-4H3,(H,53,59)(H,54,60)/t27-,28-,51-,52-/m0/s1
SMILES Code
O=C(OCc12)[C@](OC([C@H](C)NC(COCCOCC(N[C@@H](C)C(O[C@@]3(CC)c(cc4n5Cc6c4nc(cccc7)c7c6)c(COC3=O)c5=O)=O)=O)=O)=O)(CC)c1cc8n(Cc9cc%10ccccc%10nc98)c2=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 980.98 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Chuang CH, Wu PC, Tsai TH, Fang YP, Tsai YH, Cheng TC, Huang CC, Huang MY, Chen FM, Hsieh YC, Lin WW, Tsai MJ, Cheng TL. Development of pH-Sensitive Cationic PEGylated Solid Lipid Nanoparticles for Selective Cancer-Targeted Therapy. J Biomed Nanotechnol. 2017 Feb;13(2):192-03. PubMed PMID: 29377649. 2: Omar R, Bardoogo YL, Corem-Salkmon E, Mizrahi B. Amphiphilic star PEG-Camptothecin conjugates for intracellular targeting. J Control Release. 2017 Jul 10;257:76-83. doi: 10.1016/j.jconrel.2016.09.025. Epub 2016 Sep 24. PubMed PMID: 27677603. 3: Song ZL, Chen HL, Wang YH, Goto M, Gao WJ, Cheng PL, Morris-Natschke SL, Liu YQ, Zhu GX, Wang MJ, Lee KH. Design and synthesis of novel PEG-conjugated 20(S)-camptothecin sulfonylamidine derivatives with potent in vitro antitumor activity via Cu-catalyzed three-component reaction. Bioorg Med Chem Lett. 2015 Jul 1;25(13):2690-3. doi: 10.1016/j.bmcl.2015.04.060. Epub 2015 May 6. PubMed PMID: 25987370; PubMed Central PMCID: PMC4768722. 4: Scott LC, Yao JC, Benson AB 3rd, Thomas AL, Falk S, Mena RR, Picus J, Wright J, Mulcahy MF, Ajani JA, Evans TR. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Cancer Chemother Pharmacol. 2009 Jan;63(2):363-70. doi: 10.1007/s00280-008-0746-2. Epub 2008 Apr 9. PubMed PMID: 18398613. 5: Posey JA 3rd, Saif MW, Carlisle R, Goetz A, Rizzo J, Stevenson S, Rudoltz MS, Kwiatek J, Simmons P, Rowinsky EK, Takimoto CH, Tolcher AW. Phase 1 study of weekly polyethylene glycol-camptothecin in patients with advanced solid tumors and lymphomas. Clin Cancer Res. 2005 Nov 1;11(21):7866-71. PubMed PMID: 16278410. 6: Zhao H, Lee C, Sai P, Choe YH, Boro M, Pendri A, Guan S, Greenwald RB. 20-O-acylcamptothecin derivatives: evidence for lactone stabilization. J Org Chem. 2000 Jul 28;65(15):4601-6. PubMed PMID: 10959865. 7: Conover CD, Greenwald RB, Pendri A, Gilbert CW, Shum KL. Camptothecin delivery systems: enhanced efficacy and tumor accumulation of camptothecin following its conjugation to polyethylene glycol via a glycine linker. Cancer Chemother Pharmacol. 1998;42(5):407-14. PubMed PMID: 9771956.

View History

PEG6-(CH2CO2H)2

PEG6-(CH2CO2H)2

Featured